Open AccessCOVID-19 Myocarditis
Author(s) -
Sophia Kwon,
Eric Alter,
Sripal Bangalore,
Anolan
Publication year - 2021
Publication title -
infectious diseases in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.145
H-Index - 21
eISSN - 1536-9943
pISSN - 1056-9103
DOI - 10.1097/ipc.0000000000001016
Subject(s) - medicine , covid-19 , pandemic , myocarditis , coronavirus , disease , intensive care medicine , mortality rate , respiratory system , virology , infectious disease (medical specialty) , outbreak
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), emerged in Wuhan, China, and rapidly led to a global pandemic that affected 213 countries, more than 5.8 million cases, and 360,000 deaths worldwide as of May 28, 2020. The United States currently has the highest number of COVID-19 cases in the world and contributes to nearly a third of the global death rate. The prevalence of COVID myocarditis is unclear but generally considered rare, with estimates up to 7% of COVID-related deaths. However, these patients suffered catastrophic worsening disease with respiratory compromise requiring intubation and often death. We report the case of a patient with COVID-19-induced myocarditis who was successfully treated with dexamethasone and review the literature.